<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02470650</url>
  </required_header>
  <id_info>
    <org_study_id>Cost-Effect-Clinic</org_study_id>
    <secondary_id>2014-004820-24</secondary_id>
    <nct_id>NCT02470650</nct_id>
  </id_info>
  <brief_title>Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive</brief_title>
  <official_title>Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of
      initiation of antiretroviral treatment. three strategies of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives:

        -  patients with virologic response ratio at 48 weeks (less than 50 plasma viral load)

        -  Change in the number of CD4 cells at 48 weeks

        -  Change in body composition and mineral density bone (body and lumbar) measurement with
           DEXA (bone mineral density scan) at 48 weeks

        -  Change in markers of renal function (creatinine clearance, glomerular filtration rate -
           eGFR - estimated rate) and renal tubular function at 48 weeks

        -  Rate of mortality and clinical progression at 48 weeks

        -  general tolerability and safety: adverse events (AA) and serious AA description
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficiency (cost-effectiveness)</measure>
    <time_frame>48 weeks of initiation antiretroviral treatment</time_frame>
    <description>Antiretroviral treatment effectiveness defined by the number of patients with &lt;37 copies/ml viral load at the 48 weeks and the treatment cost defined by the sum of cost ogfthe antiretroviral treatment and all its consequences (adverse effects, changes of pattern study antiretroviral resistance in case of being necessary, days of sick leave by the patient and hospital admission days) that occur in the 48 weeks. The price of the antiretroviral treatment will be defined by Spanish official price.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the number of CD4 cells</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in the number of CD4 cells at 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with virologic response ratio copies mL plasma viral load)</measure>
    <time_frame>48 weeks</time_frame>
    <description>less than 37 copies/mL in plasma viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition and mineral density bone lumbar) measurement with DEXA</measure>
    <time_frame>48 weeks</time_frame>
    <description>Measurement baseline and at 48 weeks. DEXA Scan (Dual X-ray Absorptiometry) to Measure Bone Health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of renal function filtration rate - eGFR - estimated rate) and renal tubular function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Defined by creatinine clearance, glomerular filtration rate - eGFR - and renal tubular function at week 48 filtration rate - eGFR - estimated rate) and renal tubular function at 48 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Rate of mortality and clinical progression</measure>
    <time_frame>48 weeks</time_frame>
    <description>Defined by diagnostic AIDS diseases or death</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Patient Compliance</condition>
  <condition>Antiretroviral Therapy Intolerance</condition>
  <arm_group>
    <arm_group_label>elvitegravir/cobicistat/emtricitabine/tenofovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>darunavir+ritonavir+lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>abacavir/lamivudine+rilpivirine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elvitegravir/cobicistat/emtricitabine/tenofovir</intervention_name>
    <description>1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)</description>
    <arm_group_label>elvitegravir/cobicistat/emtricitabine/tenofovir</arm_group_label>
    <other_name>Stribild</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day</description>
    <arm_group_label>darunavir+ritonavir+lamivudine</arm_group_label>
    <other_name>prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abacavir/lamivudine</intervention_name>
    <description>Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day</description>
    <arm_group_label>abacavir/lamivudine+rilpivirine</arm_group_label>
    <other_name>Kivexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100 mg recovered tablet once a day</description>
    <arm_group_label>darunavir+ritonavir+lamivudine</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>lamivudine 300mg (Epivir) 1 recovered tablet</description>
    <arm_group_label>darunavir+ritonavir+lamivudine</arm_group_label>
    <other_name>Epivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rilpivirine</intervention_name>
    <description>rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day</description>
    <arm_group_label>abacavir/lamivudine+rilpivirine</arm_group_label>
    <other_name>Edurant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1-negative pregnancy test in women of childbearing age

          -  2- stable HIV-1 infection clinically and not take antiretroviral therapy

          -  3- viral load HIV &lt;100,000 copies

          -  4- CD4 cells &gt;100 cels/mm3

          -  5- Glomerular filtration &gt;70mlmin

          -  6- have a negative HLA B5701

          -  7-.patients should have given informed written consent

          -  8- in the opinion of the investigator, be able to follow the design of the Protocol
             visits

        Exclusion Criteria:

          -  1-. Patients who had virologic failure with any antiretroviral therapy

          -  2- evidence of prior mutations of the study drugs

          -  3- use of any anti-retroviral treatment in the 6 months prior to the entry of the
             study

          -  4- contraindication to the drugs study

          -  5- any condition that does not allow to ensure the correct compliance to the study

          -  6- uncontrolled previous psychiatric illness

          -  7- Current or active addiction or alcoholism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mallolas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pep Mallolas, MD</last_name>
    <email>jmallolas@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Josep Mallolas Masferrer</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Albert Arnaiz, MD</last_name>
      <phone>932275400</phone>
      <phone_ext>3898</phone_ext>
      <email>jaarnaiz@clinic.ub.es</email>
    </contact>
    <contact_backup>
      <last_name>ana Cruceta, MD</last_name>
      <email>acruceta@clinic.ub.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>Josep Mallolas, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>comparative effectiveness</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

